Adaptimmune Therapeutics PLC (NASDAQ:ADAP - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.27 and traded as high as $0.29. Adaptimmune Therapeutics shares last traded at $0.27, with a volume of 386,996 shares.
Analyst Upgrades and Downgrades
Several analysts have issued reports on ADAP shares. HC Wainwright decreased their price target on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Jones Trading cut shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Barclays lowered their price target on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Mizuho lowered shares of Adaptimmune Therapeutics from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $1.50 to $0.50 in a report on Thursday, June 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Adaptimmune Therapeutics has a consensus rating of "Hold" and an average price target of $1.35.
View Our Latest Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
The company has a market capitalization of $74.08 million, a P/E ratio of -1.04 and a beta of 2.18. The company has a current ratio of 2.02, a quick ratio of 1.79 and a debt-to-equity ratio of 4.24. The firm has a fifty day moving average of $0.27 and a 200 day moving average of $0.38.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $7.29 million for the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 38.91%. On average, equities research analysts anticipate that Adaptimmune Therapeutics PLC will post -0.14 EPS for the current year.
Institutional Trading of Adaptimmune Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its position in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Adaptimmune Therapeutics by 492.0% during the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. Two Sigma Investments LP lifted its position in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares during the period. Virtu Financial LLC lifted its position in Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 21,688 shares during the period. Finally, LPL Financial LLC increased its holdings in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buying an additional 94,623 shares in the last quarter. 31.37% of the stock is owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
